Abivax SA reported revenue of $0.92 million, surpassing analyst estimates of $0.80 million, signaling better-than-expected sales performance. However, the company posted a loss per share of -$1.71, missing the expected -$0.917, reflecting heavy R&D expenses typical for biotech firms. Despite the loss, Abivax maintains a strong financial position with €402.4 million in cash, a low debt-to-equity ratio of 0.10, and a current ratio of 7.86, supporting its clinical development efforts through 2029. Analysts remain optimistic, with several rating the stock as a moderate buy or better, highlighting confidence in its future prospects.
Abivax earnings report provides context for readers interested in biotech and health stocks. For readers following health-sector US stocks on Pluang, here is the market snapshot as of Sep 22, 2026 19:02 WIB: out of 101 priced stocks, 50 rose and 41 fell. Notable movers include GSK at USD 50.50 with a 1-day change of -1.14% and 100% sell order activity, Alcon AG at USD 65.57 up 1.08% with 89% sell orders, and Cassava Sciences Inc at USD 0.73 down 1.04% with 98% sell orders. Typical hold times range from 39 to 91 days among these stocks.
THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...
Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 mi...
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
A director at FormFactor sold 2,100 shares, indicating a notable insider transaction. Such sales can reflect personal financial decisions or strategic portfolio adjustments by company insiders. Investors often watch these moves for potential signals ...
